Form 4: Arcutis Biotherapeutics Director Howard G. Welgus Executes Stock Option and Sells Shares
SEC Form 4 Filing
Director Howard G. Welgus exercised stock options and sold shares of Arcutis Biotherapeutics (ARQT) on August 1, 2024, according to a Form 4 filing with the SEC.
Summary
- On August 1, 2024, Howard G. Welgus, a director of Arcutis Biotherapeutics, exercised stock options to acquire 6,614 shares of common stock at a price of $1.6806 per share.
- Welgus then sold 6,614 shares at a weighted average price of $9.8696, with individual sales ranging from $9.76 to $10.08.
- Following these transactions, Welgus directly owns 176,953 shares of Arcutis Biotherapeutics common stock.
- Additionally, Welgus indirectly owns 24,991 shares through The Welgus Living Trust.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard insider transaction disclosure. The director exercised options and sold shares, which is a common practice.
Industry Context
This filing is a routine disclosure of insider transactions. It's common for executives and directors to have pre-arranged trading plans (10b5-1) to avoid accusations of trading on inside information. The market will likely interpret this as a standard transaction unless the volume is unusually high or low compared to historical insider trading activity.
Key Dates
| Date | Description |
|---|---|
| 08/01/2024 | Date of stock option exercise and share sale. |
| 08/05/2024 | Date of Form 4 filing. |
| 03/13/2029 | Expiration date of the stock option. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.